Blog

Home/News/Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients.

    

Written by

Peter Zirbes, ESQ. A Full Service Law Office 718 544 6300